![]() ![]() “This is the first step towards taking our triple therapy for moderate to severe COPD patients and providing the same treatment option for appropriate asthma patients,” said Alessandro Chiesi, Chiesi Group Chief Commercial Officer. 7 The inhaler also contains a dose counter that allows patients to track and manage their treatment. 1,2 For asthma, this is the first triple, extrafine formulation, combination inhaler with the ability to reach the whole bronchial tree, including both the large and the small airways. 3Ĭhiesi’s triple therapy is a combination of an ICS/LABA/LAMA that contains beclometasone dipropionate (ICS), formoterol fumarate (LABA) and glycopyrronium (LAMA). 1,2 This follows the 2017 approval of this therapeutic option for the treatment of adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS/LABA, or a combination of a LABA/LAMA (long-acting muscarinic antagonist). Parma, Italy, Febru– Chiesi, an international research-focused healthcare group (Chiesi Group), announces that the European Commission has granted the marketing authorisation for Trimbow (beclometasone/formoterol/glycopyrronium), an extrafine formulation triple fixed combination therapy in a single inhaler, as a maintenance treatment for adult asthma patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and medium dose of inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous year. The Marketing Authorisation approval is based on Committee for Medicinal Products for Human Uses’ positive opinion and European Commission approval on data obtained in four clinical studies involving close to 3000 patients.1,2 This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe chronic obstructive pulmonary disease (COPD) patients. Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients.
0 Comments
Leave a Reply. |